Robert Rehm Presents at North Carolina Central University School of Law Biotechnology and Pharmaceutical Law Institute and Law Review Symposium
Raleigh, NC (March 23, 2010) – Robert Rehm, a partner in Smith Anderson’s Intellectual Property practice group, participated in a panel discussion among intellectual property law practitioners and administrators at a symposium sponsored by the North Carolina Central University School of Law Biotechnology and Pharmaceutical Law Institute and Law Review. The Symposium, entitled "Hot Topics and Developments in Biotechnology and Pharmaceutical Law," was held on Friday, March 19, 2010, at the North Carolina Biotechnology Center located in Research Triangle Park, NC.
The panel's discussion topic, "Issues Related to Developments Within Science and Intellectual Property," focused on a number of recent cases that are likely to affect the patentability of biotech-related inventions, the challenges to biotech innovation presented by a struggling economy, and the unique intellectual property development and commercialization issues faced by biotech organizations having dual research and teaching missions.
Rehm's presentation, " Whether a Separate Written Description Requirement for Patentability Based on the ‘In Possession’ Test Stifles Biotech Innovation," addressed how the United States Court of Appeals for the Federal Circuit's treatment of the written description and enablement requirements for patentability under U.S. law in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., which was reheard en banc on December 7, 2009 (decision pending), is likely to impact the ongoing vitality of biotech innovation in the United States.
